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Anti-Gal is the most abundant antibody in humans, constituting 1% of immunoglobulins. Anti-Gal binds speciﬁcally α-gal
epitopes (Galα1-3Galβ1-4GlcNAc-R). Immunogenicity of autologous tumor associated antigens (TAA) is greatly increased by
manipulating tumor cells to express α-gal epitopes and bind anti-Gal. Glycolipids with α-gal epitopes (α-gal glycolipids) injected
into tumors insert into the tumor cell membrane. Anti-Gal binding to the multiple α-gal epitopes de novo presented on the tumor
cells results in targeting of these cells to APC via the interaction between the Fc portion of the bound anti-Gal and Fcγ receptors
on APC. The APC process and present immunogenic TAA peptides and thus, eﬀectively activate tumor speciﬁc CD4+ helper T
cells and CD8+ cytotoxic T cells which destroy tumor cells in micrometastases. The induced immune response is potent enough
to overcome immunosuppression by Treg cells. A phase I clinical trial indicated that α-gal glycolipid treatment has no adverse
eﬀects. In addition to achieving destruction of micrometastases in cancer patients with advance disease, α-gal glycolipid treatment
may be eﬀective as neo-adjuvant immunotherapy. Injection of α-gal glycolipids into primary tumors few weeks prior to resection
can induce a protective immune response capable of destroying micrometastases expressing autologous TAA, long after primary
tumor resection.
1.Introduction
Destruction of detectable metastases by resection or ablation
may prolong survival, but it does not aﬀect invisible
micrometastases which can develop into lethal metastases.
Moreover, it is likely that in a large proportion of patients
treated by novel targeted therapies, micrometastases may
not be completely eliminated. This is since there is a high
probability that some metastatic cells residing far enough
from capillaries will not be susceptible to the therapeutic
eﬀectofdrugsbecauseofdiminishingconcentrationofdrugs
diﬀusing from the nearby capillary. A lasting antitumor
protection that eﬀectively destroys micrometastases may be
achieved by immunotherapy that stimulates the immune
system to react against the multiple tumor-associated anti-
gens (TAAs). This principle is demonstrated in the life-long
protection against EBV transformed polyclonal B cells which
are “kept at bay” by EBV-speciﬁc T cells. Immunosuppres-
sion (as in allograft recipients) may result in appearance
of such transformed B cells as multiclonal lymphomas due
to the suppression of protective T cell activity [1]. The
protective eﬀect of the human immune system against TAA
on tumor cells is further illustrated by the high correlation
between the extent of T cell inﬁltration within tumors and
positive prognosis reported in melanoma, ovarian cancer,
colorectal carcinoma, and other tumors [2–6]. In particular,
detailed studies of Galon and colleagues demonstrated a
distinctinversecorrelationbetweenthedensityofinﬁltrating
CD8+ and Th1 memory T cells in resected colorectal
carcinoma and the relapse of the disease [4–6]. The observed
exclusive inﬁltration of T cells into tumors without aﬀecting
normal tissues implies that the observed antitumor immune
response is aimed speciﬁcally against antigens (Ags) on
tumor cells, that is, against TAA. This further implies that2 Clinical and Developmental Immunology
eliciting an immune response against these Ags may result
in immune protection against the tumor cells expressing
them.
2. Autologous TAA asAntitumor Vaccine
TAA can be common to a given tumor in many patients
having the same type of tumor, or can be unique to the
individual patient. Immunotherapy against known common
TAA has been unsatisfactory, possibly since such TAA are of
weak immunogenicity due to their presence in low amounts
both on normal cells and on embryonic cells [7, 8]. Unique
TAA appears due to genomic instability in tumor cells and
are generated by multiple coding mutations which diﬀer
fromonepatienttotheother.Manyofthesemutationsresult
in small changes in proteins that may provide advantageous
growth to tumor cells [9–13]. Other mutations are neutral
since they do not aﬀect the structure or function of the
mutated protein. The mutated proteins can function as
autologous TAA that may elicit a protective antitumor
immune response, since they are present in tumor cells and
absent in normal cells. Such a protective immune response
against autologous TAA may be beneﬁcial in achieving
immune protection against metastatic tumor cells. The
immune system is capable of detecting and reacting against
small changes that give rise to autologous TAA. This can be
inferredfromtheextensiveimmuneresponsetobloodgroup
Ags where the diﬀerence of the small N-acetyl group on
the terminal galactosyl in blood group A, in comparison to
blood group B (i.e., GalNAcα1-3Gal and Galα1-3Gal, resp.)
is suﬃcient for inducing the production of anti-A antibody
(Ab) in blood group B individuals.
Characterization and production of the multiple autolo-
gous TAA in each individual patient for vaccinating purpose
is not feasible at present. Thus, the tumor itself is the only
current practical source for autologous TAA [14]. As with
any microbial vaccine, an eﬀective immune response against
autologous TAA requires eﬀective uptake of the tumor cells
and cell membranes by antigen presenting cells (APCs) such
as dendritic cellsand macrophages. The internalized TAA are
transported by APC to the regional lymph nodes, processed
by these cells, and presented on MHC class I and class
II molecules as TAA peptides that activate tumor-speciﬁc
CD8+ cytotoxic T cells and CD4+ Th1 cells, respectively
[15, 16]. However, vaccination with unprocessed tumor cells
obtained from the patient is usually ineﬀective since tumor
cells evolve to evade recognition by APC [7–10] and thus are
“ignored” by the immune system. This is clearly indicated by
the ability of tumor cells to reside in lymph nodes without
being aﬀected by the immune system. Moreover, TAA are
usually “concealed” from the immune system because the
tumor cytokine milieu is often suppressive toward immune
function and induces tolerance, anergy, or lymphocyte death
[17–19]. Thus, studies have been aimed to recruit APC into
the lesions by intratumoral administration of immunomod-
ulators such as GM-CSF or CpG oligonucleotides [19, 20].
Although eﬀectively recruited, the APC cannot identify
tumor cells within the lesion as cells that “ought” to be
internalized, since the tumor cells lack identifying markers
that label them for uptake by APC. Thus, uptake of tumor
cells by recruited APC is suboptimal as it is mediated by
random endocytosis [14].
It is well established that one of the most eﬀective
mechanisms by which APC as macrophages and dendritic
cells can internalize vaccinating Ags and process them for T
cell activation is the formation of immune complexes with
the microbial and tumor vaccinating Ags. The interaction
of the Fc portion of the immunocomplexed Ab molecules
with Fcγ receptors (FcγRs) on APC generates signals for Ag
internalization as well as for maturation of dendritic cells
internalizing the Ag and subsequent eﬀective stimulation
of the immune system [21–30]. Targeting tumor cells via
Fc/FcγR interaction to macrophages and dendritic cells
enables these APC to internalize TAA of the tumor cells
coated with an IgG Ab. Such targeting is feasible in all
humans that are not severely immunocompromized by
exploiting the natural anti-Gal Ab and its ligand the α-gal
epitope.
3.The NaturalAnti-GalAntibodyand
The α-galEpitope
Anti-Gal is the most abundant natural Ab in human blood,
constituting ∼1% of serum immunoglobulins [31]. It is pro-
duced throughout life in response to antigenic stimulation
by gastrointestinal bacteria [32]. Anti-Gal binds speciﬁcally
to the α-gal epitope. This epitope has the structure Galα1-
3Galβ1-4GlcNAc-R [33, 34]. The α-gal epitope is present
on cell surface glycolipids and glycoproteins of nonprimate
mammals, prosimians, and New World monkeys [35–37].
The α-gal epitope is synthesized on carbohydrate chains
of glycolipids and glycoproteins in mammalian cells by
the glycosylation enzyme α1,3galactosyltransferase (α1,3GT)
[36, 38]. Because of immune tolerance, mammalian species
producing α-gal epitopes lack the natural anti-Gal Ab. In
contrast, humans, apes, and Old World monkeys lack the α-
gal epitope due to inactivation of the α1,3GT (Ggta1)g e n e
in ancestral primates, and all produce the natural anti-Gal
antibody [35–41].
Sinceanti-Galispresentinlargeamountsinallimmuno-
competent humans and Old World monkeys, administered
α-gal epitopes form in situ immune complexes with it.
One area demonstrating this Ag/Ab interaction has been
xenotransplantation in which pig cells or pig organs are
transplanted into humans or monkeys. Anti-Gal binding
to the multiple α-gal epitopes on cells of pig xenografts
causes the rapid rejection of such xenografts (e.g., pig heart
or kidney) in humans, or in monkeys, by complement-
dependent cytotoxicity (CDC) and by antibody-dependent
cell cytotoxicity (ADCC) [42–45]. As described below, injec-
tionofα-galglycolipidsintotumorsinamouseexperimental
model producing anti-Gal Ab results in expression of α-
gal epitopes on tumor cells within the injected lesion, in a
manner similar to the expression of these epitopes on pig
cells. The subsequent binding of anti-Gal Ab to the α-gal
epitopes de novo expressed on the tumor cells results in
destruction of tumor cells as in xenograft rejection and the
targeting of tumor cells and cell membranes to APC.Clinical and Developmental Immunology 3
4.Anti-Gal-MediatedTargeting of
AgstoAPCandIncreasedImmunogenicityin
the OVA model
The principle of anti-Gal-mediated increased immunogenic-
ity of vaccines by formation of immune complexes with α-
gal epitopes could be illustrated with hen egg ovalbumin
(OVA) as the immunizing Ag [46]. OVA serves as an eﬀective
model for an immunizing Ag since there are several highly
sensitive immunological tools that enable evaluation of
the internalization and processing of this Ag in APC and
presentation of its most immunogenic peptide SIINFEKL on
class I MHC molecules. Furthermore, activation of CD8+
T cells can be evaluated following the speciﬁc interaction
with SIINFEKL when presented on class I MHC molecules.
The immune response was analyzed in the experimental
model of α1,3GT knockout mice (KO mice) which lack
α-gal epitopes and produce the anti-Gal Ab [47]. OVA
was encapsulated within liposomes that express multiple α-
gal epitopes (referred to as α-gal liposomes) [46, 48, 49].
Uptaking and processing of OVA encapsulated within α-
g a ll i p o s o m e sb yK Om o u s eA P Cw a sf o u n dt ob es e v e r a l
fold higher when the liposomes bound anti-Gal than in
the absence of this Ab. This increased uptake was due to
Fc/FcγR interaction between the Fc portion of anti-Gal on
liposomes and FcγRo nA P C[ 46]. APC in draining lymph
nodes displayed 5–8 fold higher presentation of SIINFEKL
than APC in draining lymph nodes of mice lacking anti-Gal.
Accordingly, the activation of SIINFEKL speciﬁc T cells as
measured by intracellular staining for IFNγ production and
by binding of tetramers carrying SIINFEKL was 2–6 fold
higher in the presence of anti-Gal in the immunized mice
than in the absence of this targeting Ab [46]. In addition,
cytolytic activity of SIINFEKL-speciﬁc T cells was ∼8f o l d
higher and the titer of anti-OVA Abs was 32 fold higher
in vaccinated mice that had the anti-Gal Ab than in mice
lacking this Ab. These studies conﬁrmed the hypothesis
that anti-Gal binding to vaccinating Ags presenting α-gal
epitopes induces eﬀective uptake and processing of the Ag
by APC and increased transport to draining lymph nodes.
In the lymph nodes the immunogenic peptides presented
by APC induce a markedly higher activation of CD8+
and CD4+ T cells than in the absence of this mechanism
[46]. This conclusion is further supported by observations
on the immune response to inﬂuenza virus vaccine and
to gp120 of HIV following anti-Gal-mediated targeting to
APC. Inactivated inﬂuenza virus processed enzymatically
to express α-gal epitopes elicited a 100-fold higher speciﬁc
CD4+ T cell response and anti-inﬂuenza Ab response and
∼5 fold higher CD8+ T cell response than vaccinating
virus lacking α-gal epitopes [50]. Accordingly, KO mice
immunizedwithvirusvaccinepresentingα-galepitopeswere
∼11 fold more resistant to challenge with live virus than
KO mice immunized with virus lacking α-gal epitopes [50].
Similarly, gp120 envelop glycoprotein of HIV processed to
express α-gal epitopes was found to elicit in KO mice ∼
100 fold higher T cell response (determined by ELISPOT)
and anti-gp120 Ab response (determined by ELISA) than
gp120 lacking α-gal epitopes [51]. All these studies in KO
mice suggested that manipulation of autologous tumor cells
in cancer patients to express α-gal epitopes may result in
conversion of such cells into eﬀective vaccines that elicit a
protectiveimmuneresponseagainstautologousTAAbecause
of their eﬀective anti-Gal-mediated targeting to APC.
5.IncreasedImmunogenicityFollowing
Anti-Gal-MediatedUptake of Tumor Cells
by APC
Studies on increasing immunogenicity of TAA by anti-Gal-
mediated targeting of tumor cells to APC were initially
performed with the mouse melanoma B16 cell line, lacking
α-gal epitopes, and processed to express these epitopes by
stable transfection with the α1,3GT gene. These cells were
irradiated and injected into anti-Gal producing KO mice
[52–54]. Vaccination with irradiated B16 cells expressing α-
galepitopeswasfoundtoelicitaprotectiveimmuneresponse
that prevented tumor growth following challenge with live
tumor cells lacking this epitope [52, 54]. Such protection
was also found in mice challenged with live melanoma
cells prior to the immunization with the irradiated tumor
cells expressing the α-gal epitopes [53]. Recently, a similar
protective eﬀect of tumor cells expressing α-gal epitopes has
been demonstrated in a pancreatic adenocarcinoma model
in KO mice [55]. The increased immunogenicity of TAA
in both melanoma and pancreatic adenocarcinoma models
was shown to be associated with eﬀective anti-Gal-mediated
uptake of the vaccinating cells by APC [52–55].
The method of genetic manipulation by stable trans-
fection with α1,3GT gene is eﬀective in inducing α-gal
epitope expression in cell lines since it requires cell division
for the insertion of this gene into the DNA of the tumor
cells. Because of the need for extensive cell division, this
genetic manipulation is not eﬀective in vivo in solid tumors
that are injected with a vector containing the α1,3GT
gene. Introduction of the α1,3GT gene into tumor cells
and transient expression of α-gal epitopes was also found
to be eﬀective in cell lines using an adenovirus vector
containing this gene [56]. Accordingly, immunization with
B16 melanoma cells transduced with adenovirus containing
the α1,3GT gene was found to elicit immune protection
against the tumor challenge [56]. However, injection of
this vector into tumor lesions resulted in a very limited
expression of α-gal epitopes because of poor diﬀusion of
the injected virus beyond the injection area (unpublished
observations). An alternative method has been developed for
invivoexpressionofα-galepitopesonautologoustumorcells
which consists of intratumoral injection of α-gal glycolipids.
6. α-GalGlycolipids Insert α-galEpitopes
intothe Membrane of Tumor Cells within
Treated Lesions
α-Gal glycolipids are glycolipids consisting of a ceramide
lipid tail and a carbohydrate chain with one or several
carbohydrate branches (antennae), all of which are capped
with the α-gal epitope [57]. A representative α-gal glycolipid4 Clinical and Developmental Immunology
with 10 carbohydrate units (ceramide decahexoside) and
two branches is illustrated in Figure 1(a).T h en u m b e ro f
branches carrying α-gal epitopes can be 1–5, or more,
all having the α-gal epitope as the terminal carbohydrate
structure. Rabbit red blood cells (RBCs) were found to be
av e r yr i c hs o u r c eo fα-gal glycolipids. These RBC have on
their membrane α-gal glycolipids with 5 carbohydrates and
with longer chains that increase in size by increment of 5
carbohydrate (i.e., 10, 15, 20, and up to 40 carbohydrates
(with the exception of a glycolipid with 7 carbohydrates))
[58–63]. Each increment also generates a new branch capped
with α-gal epitopes [58–63]. α-Gal glycolipids are extracted
from rabbit RBC membranes by their incubation in a
mixture of chloroform and methanol [57]. The hydrophilic
glycolipids are further separated from the hydrophobic
phospholipids and cholesterol by a process called Folch
partition [64]. Extracted α-gal glycolipids dissolve in water
or PBS in a ball-like forms called micelles in which the
hydrophobic portion of the glycolipid (i.e., the lipid tail) is in
the core of the micelle whereas the hydrophilic carbohydrate
chain protrudes into the aqueous surrounding.
Incubation of α-gal glycolipid micelles with tumor cells
for 2h at 37◦C results in spontaneous insertion of these
glycolipids into the tumor cell membranes. This is since the
hydrophobic lipid tail of the α-gal glycolipid is energetically
much more stable when surrounded by the phospholipids
of the lipid bilayer in the cell membrane than when it is
surrounded by water molecules in the micelle. The insertion
of α-gal glycolipids into the tumor cell membranes results
in presentation of multiple α-gal epitopes on tumor cells.
These epitopes protrude from the tumor cell membrane and
readily bind the anti-Gal Ab (Figure 1(b))[ 57]. The eﬀective
in vitro insertion α-gal glycolipids into B16 melanoma cells
[57] and into human tumor cells [65] suggested that a
similar insertion may occur in vivo in tumor lesions injected
with these glycolipids. Eﬀective in vivo insertion into a
large proportion of the tumor cells within the lesion is
achieved by injection in several regions of the tumor. It
should be stressed that this insertion is not selective and
occurs in both malignant and normal cells in the lesion.
This in vivo insertion could be visualized in B16 melanoma
lesions by staining with a lectin speciﬁc for α-gal epitopes
(Bandeiraea(Griﬀonia)simplicifolia IB4)[57].Injection ofα-
gal glycolipid micelles into tumor lesions is likely to result in
several processes includingthe following.
6.1. Recruitment of APC by Complement Cleavage Chemotac-
tic Factors. Anti-Gal/α-gal epitope interaction activates the
complement system and generates chemotactic complement
cleavage peptides such as C3a and C5a. These chemotactic
factors induce an extensive recruitment of APC such as
macrophagesanddendriticcellsintothetreatedlesion.Thus,
this treatment enables the immune system to overcome the
immunosuppressive conditions within solid tumor lesions,
induced by microenvironment and local cytokine milieu and
by regulatory T (Treg) cells [17–19, 65].
6.2.Insertionofα-galGlycolipidsintoTumorCellMembranes.
α-Gal glycolipids injected as micelles into lesions sponta-
neously insert into the tumor cell membranes, resulting in
thepresentation of multiple α-galepitopes onthemembrane
of the tumor cells (Figure 1(b)).
6.3. Destruction of Tumor Cells by Anti-Gal Binding to α-
gal Epitopes on the Cells. Anti-Gal binding to α-gal epitopes
of the inserted glycolipids mediates tumor cell destruction
in a process similar to xenograft rejection. Bound anti-Gal
IgM molecules activate complement and induce cell lysis by
complement-dependent cytotoxicity (CDC) [57]. Binding of
anti-Gal IgG molecules to α-gal epitopes on cells further
facilitates Ab-dependent cell-mediated cytolysis of the cells
(ADCC) [42].
6.4. Targeting of Tumor Cells to APC for Their Conversion into
Endogenous TAA Vaccine. Anti-Gal IgG molecules bound
to α-gal epitopes on tumor cells in treated lesions further
bind via their Fc portion to FcγR on dendritic cells and
macrophages and stimulate these APC to internalize the
opsonized tumor cells and cell membranes with the autol-
ogous TAA (Figure 1(b)). The internalized TAA, transported
by the APC to draining lymph nodes, are processed and the
immunogenic TAA peptides presented for the activation of
tumor-speciﬁcTcells.TheseactivatedTcellsleavethelymph
nodes a circulate in order to seek and destroy tumor cells in
micrometastases which express the immunizing TAA.
7. Treatment of Mouse Melanoma by
IntratumoralInjectionof α-galGlycolipids
Prevents Tumor Growth
Evaluation of α-gal glycolipid immunotherapy was per-
formed in the model of KO-mice-bearing syngeneic cuta-
neous B16 melanoma [57, 65]. Melanoma lesions with a size
of ∼5mm were formed within one week after subcutaneous
injection of 106 melanoma cells of the cell line B16. Injection
of 1mg α-gal glycolipids into such lesions resulted in in situ
insertion of these glycolipids into tumor cell membranes
which could be demonstrated by immunostaining of tumor
sections with Bandeiraea simplicifolia IB4 lectin which binds
speciﬁcally to α-gal epitopes [57]. The interaction between
α-gal glycolipids injected into B16 melanoma lesions of KO
mice and the anti-Gal Ab further resulted in activation of
the complement system and the formation of complement
cleavage chemotactic factors that induced rapid recruit-
ment of dendritic cells and macrophages. Thus, eﬀective
recruitment could be demonstrated already within 48h after
injection [57]. This recruitment further increases within
7 days, but it could not be observed in PBS-injected
tumors, implying that in the absence of α-gal glycolipids, the
immune system is “oblivious” to the growing tumor [57].
A similar rapid recruitment of macrophages was observed
in KO mouse skin after injection of α-gal nanoparticles
(submicroscopic liposomes) comprised of α-gal glycolipids,
phospholipids, and cholesterol [49]. This recruitment was
inhibited by cobra venom factor which blocks activation of
the complement system thereby preventing generation of
complement chemotactic factors [49].Clinical and Developmental Immunology 5
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Figure 1: (a) Ceramide decahexoside as a representative α-gal glycolipid. This glycolipid has 10 carbohydrate branched chains. The α-gal
epitope (Galα1-3Galβ1-4GlcNAc-R) marked by the broken line rectangles caps both carbohydrate branches. The terminal α-galactosyl (Gal)
unit is linked α1,3 to the penultimate Gal of the carbohydrate chain by the glycosylation enzyme α1,3galactosyltransferase (α1,3GT). The
lipid portion of α-gal glycolipids (ceramide) anchors the carbohydrate portion in the cell membrane via the two fatty acid tails. (b) Anti-
Gal-mediated targeting of tumor cells to APC in lesions injected with α-gal glycolipids. Intratumoral injection of α-gal glycolipids results in
insertion of these glycolipids in tumor cell membranes. Anti-Gal IgG binds in situ to α-gal epitopes on the inserted glycolipids. Subsequent
interaction between the Fc portion of the bound anti-Gal and FcγR on the APC (illustrated as a dendritic cell) induces uptake of intact
or lysed tumor cells by APC, resulting in eﬀective internalization of the tumor-associated antigens (TAAs). Internalized TAA are processed
and various immunogenic TAA peptides (, , ) are presented by the APC in association with class I and class II MHC molecules. These
immunogenic peptides can activate tumor speciﬁc cytotoxic and helper T cells and elicit a protective antitumor immune response.
B16 melanoma is a very aggressive tumor that usually
doubles its size in KO mouse skin every 4–8 days. However,
the majority (65%) of melanoma lesions injected with α-
gal glycolipids displayed no additional growth or regression
in lesion size [57]. The remaining tumors displayed slower
growth than control lesions injected with PBS (all of
which did not stop growing). In vitro analysis of anti-Gal-
mediated killing of B16 melanoma cells presenting α-gal
epitopes indicated that both complement depended cytolysis
and ADCC contribute to the destruction of tumor lesions
injected [57]. A similar complement-mediated cytolysis
by anti-Gal was observed in human melanoma cells that
were incubated with α-gal glycolipids, then incubated with
human serum containing anti-Gal Ab and complement
[65].
8. Melanoma Lesions Injectedwith α-gal
Glycolipids AreConverted into
Autologous Vaccines
Similar to the lack of immune response against tumors
in patients with advanced disease, there is no protective
immune response in KO mice against untreated B16 tumors.
This is indicated by the complete lack of APC inﬁltration in
B16 melanoma tumors injected with PBS [57]. Moreover,
melanoma lesions ablated by intratumoral injection of
ethanol elicit no protective immune response against distant
untreatedlesions [65]. However, intratumoral injection of α-
galglycolipidsconvertsthetreatedlesionintoanendogenous
autologous tumor vaccine which elicits an immune response
against autologous melanoma-associated antigens (MAAs)
on the tumor cells. By using B16 melanoma cells producing
OVA as a surrogate TAA and employing detection methods
as those described above for α-gal liposomes containing
OVA [46], it was possible to demonstrate eﬀective in vivo
uptake of the tumor cells by APC in lesions injected with
α-gal glycolipids [57]. In addition, the subsequent transport
and presentation of SIINFEKL (the immunodominant OVA
peptide) in the draining lymph nodes was much higher in
micewithα-galglycolipid-injectedtumorsthaninthosewith
PBS-injected tumors, that is, the number of SIINFEKL pre-
senting APCin thedraining lymphnode in theformergroup
was much higher than in the latter. This, in turn, resulted
in a much higher number of tumor-speciﬁc activated T cells
which mediated a systemic protective antitumor immune
response. These T cells could be demonstrated in vitro by
determining the number of SIINFEKL-speciﬁc CD8+ T cells
in mice with B16/OVA treated with α-gal glycolipids versus
PBS and by demonstrating the marked increase in their
cytolytic activity against cells presenting SIINFEKL on class
I MHC molecules [57]. A similar increase in MAA-speciﬁc
T cells was observed in B16-bearing mice treated with α-gal
glycolipids versus PBS control by analysis of IFNγ secretion
in ELISPOT following incubation with immunodominant
MAA peptides of tyrosinase and gp100 [65].6 Clinical and Developmental Immunology
The in vivo protective eﬀect of α-gal glycolipids was
determinedbyevaluationofdistanttumordevelopmentafter
treatment. KO mice producing anti-Gal Ab and bearing B16
melanoma lesions received 3 weekly injections of 1mg α-gal
glycolipids. One day after the third injection, the mice were
challenged in the contralateral ﬂank with 5 × 105 B16 cells
and subsequent tumor growth was monitored. The majority
(65%) of treated mice displayed no tumor growth in the
challenge site whereas the remaining mice displayed a slower
tumor growth than PBS-injected tumors [57]. Another
control group consisted of mice in which the primary
tumor was ablated by intratumoral injection of ethanol,
similar to tumor ablation in the clinical setting. Ablation by
ethanol successfully destroyed treated tumors, however this
treatment did not induce any protective immune response
against challenge with B16 cells in the contralateral ﬂank
[65].
Immunotherapy with α-gal glycolipids was further eval-
uated for inducing a protective immune response against
an established distant micrometastasis. A micrometastasis
was simulated by subcutaneous inoculation in the left ﬂank
with 104B16 cells at the same time that the right ﬂank
was inoculated with 106 tumor cells. After 5-6 days, the
tumor developing in the right ﬂank reached a size of 5mm
(“primary” tumor) whereas in the left ﬂank inoculation site
the tumor was not visible at that time point and simulated
an established distant micrometastasis. The visible primary
tumor received two intratumoral injections of either PBS or
of α-gal glycolipids. In mice injected with PBS the simulated
distant micrometastasis developed into a 4–12mm lesion
within 20 days. However, in 50% of mice in which primary
tumors were injected with α-gal glycolipids, no lesions
developed from the micrometastasis during the 30 days
monitoring period. In the remaining mice, the simulated
micrometastases developed, however, at a slower rate than
that in the PBS-treated mice [65]. Overall, the prevention of
tumor growth in the contralateral ﬂank following injection
of the primary tumor with α-gal glycolipids reﬂects the
induction of a protective immune response against autol-
ogous MAA due to the conversion of the injected tumors
into autologous vaccine. This further suggests that a similar
treatment in humans may elicit an immune response capable
of destroying micrometastases, thereby preventing them
from developing into lethal metastases.
9. α-GalGlycolipidTreatment Activates
Tumor-Speciﬁc CD8+ T Cellsand Overcomes
Regulatory TCellActivity
Adoptive transfer studies were performed with spleen
lymphocytes from tumor-bearing mice treated with α-gal
glycolipids that were transferred into na¨ ıve KO mice. These
studies aimed to identify the lymphocytes that mediate
the protective immune response against the tumor. The
recipients were inoculated subcutaneously with 5 × 105
B16 cells. This inoculation was performed 24h prior to
the adoptive transfer of 40 × 106 spleen lymphocytes from
B16 tumor-bearing donors treated with α-gal glycolipids or
with PBS. In na¨ ıve mice that did not receive transferred
lymphocytes, the challenging tumor cells developed into
5–7mm lesions within 10 days and into a 20mm lesion
within 20–25 days. Adoptive transfer of lymphocytes from
tumor-bearing mice treated with α-gal glycolipids resulted
in prevention of tumor growth in ∼70% of the recipi-
ents and the remaining recipients displayed slower tumor
growth than in control mice [65]. However, when the
transferred lymphocytes were depleted in vitro of CD8+ T
cells (by anti-CD8-coated magnetic microbeads), the pro-
tective eﬀect of the transferred lymphocytes was eliminated
[65].
Lymphocytes transferred from mice with PBS-treated
tumors had almost no protective eﬀect and tumor growth
was observed in >75% of the recipients [65]. Nevertheless,
depletion of CD4+ T cells from the transferred lymphocytes
resulted in increased protection against the tumor challenge
[65]. These ﬁndings suggest that, in accordance with previ-
ous reports [66, 67], mice bearing B16 melanoma or other
tumors have CD4+ regulatory T (Treg) cells that inhibit the
development of a protective antitumor immune response.
Thus, treatment with α-gal glycolipids seems to elicit a
protective immune response potent enough to overcome the
suppressive eﬀect of endogenous Treg in the tumor-bearing
mice [65].
10.Feasibilityof α-GalGlycolipidin
Immunotherapy of Cancer Patients
Instudiesinhumans,anti-Galfromhumanserumwasfound
to induce eﬀective targeting of tumor cells presenting α-gal
epitopes for uptake by human macrophages and dendritic
cells via Fc/FcγR interaction [68]. The in vivo safety of
such targeting by α-gal glycolipid immunotherapy has been
evaluated in a Phase I clinical trial under IND-12946 at
UMass Medical Center in patients with advanced solid
tumors. Patients with a variety of advanced cancers received
a single intratumoral injection of α-gal glycolipid into one of
their tumor lesions. The administration of α-gal glycolipids
was performed by endoscopy, laparoscopy, or ultrasound
guidance,dependingonthesiteofthetumor.Usingstandard
Phase I dose escalation, each cohort of patients received an
intratumoral injection of 0.1, 1.0, or 10mg α-gal glycolipids.
All participating patients displayed no treatment-associated
toxicity (manuscript in preparation). Based on these studies,
the dose of α-gal glycolipids to be used in future Phase II
studies is planned to be 10mg. It is expected that the results
of α-gal glycolipid treatment will vary from one patient to
the other, depending on the immunogenicity of the various
TAA in the individual patient and on the potency of the
immune system in the treated patient. It is possible that in a
proportion of the patients, the combination of eﬀective TAA
and potent immune system may result in the generation of a
protectiveimmuneresponseagainsttheautologousTAAthat
is eﬀective enough to destroy tumor cells presenting these
TAA.
The studies in mice strongly suggest that the elicited
immune response against autologous TAA is potent enoughClinical and Developmental Immunology 7
to destroy small groups of tumor cells, that is, micrometas-
tases. However, it is not clear at present whether the α-gal
glycolipid immunotherapy can elicit an immune response
capable of destroying visible metastases. Studies in mice with
B16 melanoma lesions [52] have demonstrated the eﬀective
destruction of the outer regions of visible tumors whereas
the inner regions are not aﬀected because of the inability of
the T cells to inﬁltrate the core of such metastases. In view
of the recent advances in immunotherapy by nonspeciﬁc
modulators of the immune system such as the monoclonal
Ab ipilimumab (anti-CTLA4 Ab enhancing T cell response),
it may be possible that combination of such treatments
with α-gal glycolipid treatment will have a synergistic
immunoprotective eﬀect. This is since the generation of
activated T cells with autologous TAA speciﬁcity following
the α-gal glycolipid treatment will be greatly enhanced by the
subsequent “nonspeciﬁc” activation of the immune system
by immunomodulators. Thus, it is possible that such a
combination may induce a protective antitumor immune
response that eﬀectively destroys both micrometastases and
visible metastases.
In addition to the possible use of α-gal glycolipids in
immunotherapy of patients with advanced tumor, this treat-
ment may be beneﬁcial in improving prognosis when used
as part of neoadjuvant immunotherapy in high-risk patients,
prior to the resection of the primary tumor. One speciﬁc
example may be mammary carcinoma. In a substantial
proportion of women with mammary carcinoma, tumors
originating from micrometastases reappear months to years
after the resection of the primary tumor. In the suggested
therapy, the primary mammary tumor is injected with α-
gal glycolipids immediately after detection. The tumor is
resected 3-4 weeks after this injection, as part of the standard
clinical care. This time frame will provide a suﬃcient period
fortheAPCtointernalizeautologousTAA,transportthemto
the draining lymph nodes, and activate the immune system
to react against tumor cells expressing these TAA. Thus, long
after the resection of the primary tumor, the immune system
may be able to continue detecting and destroying tumor cells
withinmicrometastases,therebypreventingthedevelopment
of lethal metastases.
11. Conclusions
A protective immune response against tumors can be
achievedbyactivatingtheimmunesystemtoreactagainstthe
full range of autologous tumor-associated antigens (TAAs).
Many of these TAA diﬀer from one cancer patient to the
other and are formed by various mutations due to genomic
instability. Presently, it is diﬃcult to identify the multiple
autologous TAA in each patient in order to synthesize the
various TAA peptides for vaccine preparation. Therefore,
the tumor itself may serve as a source for the vaccinating
TAA. In order for the tumor to function as a vaccine, tumor
cells and cell membranes have to be eﬀectively targeted
to antigen-presenting cells (APCs) which process the TAA,
transport them to the draining lymph nodes, and present
the immunogenic TAA peptides for the activation of tumor-
speciﬁc T cells. Tumor cells usually evolve to be “ignored” by
APC and to develop without eliciting an antitumor immune
response. Immunogenicity of tumors can be increased by
manipulatingthemtoexpressα-galepitopes(Galα1-3Galβ1-
4GlcNAc-R). Injection of glycolipids with α-gal epitopes (α-
gal glycolipids) in the form of micelles into tumors results
in spontaneous insertion of the lipid tail of these glycolipids
into the cell membrane and the presentation of multiple
α-gal epitopes on the tumor cell membranes. This results
in binding of the natural anti-Gal antibody (constituting
1% of immunoglobulins in humans) to its ligand, the α-
gal epitope on tumor cells within the treated lesion. Anti-
Gal opsonizes the tumor cells and targets them to APC via
the interaction between the Fc portion of the bound anti-
Gal and Fcγ receptors on APC. Such interaction induces
eﬀective uptake of the opsonized tumor cells by APC, and
subsequent processing and presentation of TAA peptides.
T h ee l i c i t e di m m u n er e s p o n s ei sp o t e n te n o u g ht oo v e r c o m e
the immunosuppressive eﬀect of regulatory T cells and to
activate tumor-speciﬁc T cells which can destroy tumor
cells within micrometastases. A phase I study (IND 12946)
in patients with advanced solid tumor has indicated that
intratumoralinjectionof0.1,1.0,and10mgα-galglycolipids
has no adverse eﬀects. This immunotherapy aims to destroy
micrometastases in cancer patients with advance disease. In
addition, injection of α-gal glycolipids into primary tumors
few weeks prior to resection may convert the lesion into a
temporary autologous tumor vaccine which induces a pro-
tective immune response that will destroy micrometastases,
long after the primary tumor has been resected.
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